A literature search of Pub Med/MEDLINE looking specifically at the studies that investigated the effects of increased doses of NSAHs in patients with all subtypes of CU was conducted.
In vitro studies have shown that bilastine has a high specific affinity for the H1-receptor but it has no or very low affinity for 30 other tested receptors.
The affinity for the H1 receptor is 3 and 6 times higher than for cetirizine and fexofenadine, respectively [10, 11].
Bilastine belongs to the piperidine class of antihistamines as do loratadine, desloratadine, and fexofenadine.
Like other antihistamines bilastine is an H1 receptor inverse agonist.
The proportions of patients responding to the therapy were compared using the Fisher’s exact test with a significance level of p Twelve studies that investigated the effects of higher doses of NSAHs were identified in this search.